Reach the market faster and with greater probability of success
Assess Biosimilarity Sooner – With innovator-specific Biosimilar CMC Analytical Master Files containing pre-established methods and preliminary reference data

Make Better Decisions – Through rigorous and comprehensive testing methodologies developed to enable early and thorough assessment of biosimilarity

Smarter Advancement – Via a phase-appropriate, molecule management approach with the development and product lifecycle in mind

Three Options – Provide you flexibility wherever your biosimilar is in the development or product lifecycle: 
  • Testing solutions
  • Evaluation of your data
  • Consultative insights
Covance respects your Privacy.
Manage your Subscriptions.
© Copyright 2019 Covance Inc. All rights reserved.

Covance Biosimilar CMC Analytical Master Files are unique guides and the foundation for risk-mitigated biosimilarity assessment, biosimilar testing and client data evaluation. 16 marketed innovator targets have pre-established CMC Analytical Master Files completed, in development, or planned. 
Service Profile: Avastin® (Bevacizumab) Biosimilar CMC Analytical Solutions
Service Profile: Humira® (Adalimumab) Biosimilar CMC Analytical Solutions
Service Profile: Eylea® 
(Aflibercept) Biosimilar CMC Analytical Solutions